

# Long-term follow-up of the next generation PI3Kδ inhibitor TGR-1202 demonstrates safety and high response rates in NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab

Owen A. O'Connor, MD, PhD<sup>1</sup>, Ian W. Flinn, MD, PhD<sup>2,3</sup>, Matthew Lunning, DO<sup>4</sup>, Julie Vose, MD<sup>4</sup>, Nathan Fowler, MD<sup>5</sup>, Loretta Nastoupil, MD<sup>5</sup>, Susan O'Brien, MD<sup>6</sup>, Marshall T. Schreeder, MD<sup>7</sup>, Manish R. Patel, MD<sup>3,8</sup>, Timothy S. Fenske, MD<sup>9</sup>, Danielle M. Brander, MD<sup>10</sup>, Tanya Siddiqi, MD<sup>11</sup>, Christopher Flowers, MD<sup>12</sup>, Jan A. Burger, MD<sup>5</sup>, William G. Wierda<sup>5</sup>, John G. Kuhn, Pharm.D.<sup>13</sup>, Peter Sportelli<sup>14</sup>, Hari P. Miskin, MS<sup>14</sup>, Michael S. Weiss<sup>14</sup> and Howard A. Burris III, MD<sup>2,3</sup>


<sup>1</sup>Columbia University Medical Center, New York, NY; <sup>2</sup>Tennessee Oncology, PLLC, Nashville, TN; <sup>3</sup>Sarah Cannon Research Institute, Nashville, TN; <sup>4</sup>University of Nebraska Medical Center, Omaha, NE; <sup>5</sup>MD Anderson Cancer Center, Houston, TX; <sup>6</sup>University of California Irvine, Orange, CA; <sup>7</sup>Clearview Cancer Institute, Huntsville, AL; <sup>8</sup>Florida Cancer Specialists, Sarasota, FL; <sup>9</sup>Medical College of Wisconsin, Milwaukee, WI; <sup>10</sup>Duke University Medical Center, Durham, NC; <sup>11</sup>City of Hope National Medical Center, Duarte, CA; <sup>12</sup>Emory University/Winship Cancer Institute, Atlanta, GA; <sup>13</sup>University of Texas Health Science Center at San Antonio, San Antonio, TX; <sup>14</sup>TG Therapeutics, Inc., New York, NY;

## Background

### TGR-1202

- PI3Kδ is highly expressed in cells of hematopoietic origin and is often upregulated in lymphoid malignancies
- TGR-1202 (TGR) is a next generation PI3Kδ inhibitor, with a unique structure and activity profile distinct from other PI3Kδ inhibitors in development, including:

- A prolonged half-life that enables once-daily dosing
- A differentiated safety profile from other PI3Kδ inhibitors in development




Fold-selectivity				
Isoform	PI3Kα	PI3Kβ	PI3Kγ	PI3Kδ
TGR-1202	>1000	>50	>48	1
<sup>1</sup> Idelalisib	>300	>200	>40	1
<sup>2</sup> PI-145	>640	>34	>11	1

<sup>1</sup>Flinn et al. 2009, <sup>2</sup>Porter et al. 2012

### Ublituximab

- Ublituximab (TG-1101, UTX) is a novel, chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen, and glycoengineered to enhance affinity for all variants of FcγRIIIa receptors, thereby demonstrating greater antibody-dependent cellular cytotoxicity (ADCC) activity than rituximab and ofatumumab.
- Phase I trials of single agent ublituximab in patients with relapsed/refractory CLL and NHL reported impressive response rates with rapid and sustained lymphocyte depletion.



## Results

### Demographics

Evaluable for Safety (n)	165 (90 Single Agent, 75 Combo with UTX)	
Median Age, years (range)	65 (22 - 86)	
Male/Female	106/59	
Histology	CLL	43
	FL	42
	DLBCL	40
	MZL	11
	HL	11
	MCL	8
	SLL	3
	WM	3
	T-Cell	2
	HCL	1
Richter's	1	
Median ECOG	1	
Prior Therapies, median (range)	3 (0 - 14)	
Patients with ≥ 3 Prior Therapies (%)	94 (57%)	
Patients Refractory to Prior Therapy (%)	85 (52%)	

### Safety


#### All Causality AE's Occurring in ≥ 10% of Patients (n = 165)

Adverse Event	All Grades		Grade 3/4	
	N	%	N	%
Diarrhea	78	47%	5	3%
Nausea	74	45%	2	1%
Fatigue	61	37%	5	3%
Vomiting	44	27%	0	0%
Neutropenia	34	21%	30	18%
Cough	32	19%	0	0%
Dyspnea	30	18%	6	4%
Dizziness	29	18%	0	0%
Headache	28	17%	2	1%
Pyrexia	26	16%	2	1%
Decreased appetite	26	16%	0	0%
Rash	26	16%	6	4%
Sinusitis	25	15%	2	1%
Anemia	24	15%	9	5%
Constipation	24	15%	1	1%
Insomnia	23	14%	0	0%
Hypokalemia	22	13%	5	3%
Back pain	20	12%	1	1%
Abdominal pain	18	11%	4	2%
Upper respiratory infection	18	11%	0	0%


- <8% of patients discontinued due to a TGR-1202 related AE
- 13% of patients had a TGR-1202 dose reduction
- Grade 3/4 AST/ALT increase was 3% (8% all grades), predominantly observed above the Phase 3 dose
- Grade 3/4 pneumonia occurred in 5% of patients (8% all grades)
- Two events of pneumonitis (<1.5%) were reported
- Two cases of colitis (<1.5%) have been reported at doses exceeding the Phase 3 dose and did not appear to be time dependent (1000 mg and 1200 mg, at 4 mos. and 24 mos., respectively, after initiating therapy).

### Efficacy

#### Patients Treated at "Higher Doses" of TGR-1202 Best Percent Change from Baseline in Disease Burden




Median Duration of Response for TGR + UTX: 12.1 Months



Median Duration of Response for TGR + UTX Not Reached (med follow-up 15.8 mos)

#### Duration on Study (n=165)



- Extended durations of exposure:
  - 80 patients for 6+ cycles
  - 43 patients for 12+ cycles
  - 14 patients for 24+ cycles
  - Longest patients on daily TGR-1202 for 3+ years

#### Overall Response Rate At Phase 3 Dose

Patients Exposed to TGR-1202 at 800 Micro						
Type	Pts (n)	CR (n)	PR (n)	ORR n (%)	SD (n)	PD (n)
DLBCL	7	1	3	4 (57%)	2	1
iNHL	17	3	6	9 (53%)	6	2

- iNHL = FL & MZL
- Higher Doses: 1200 mg of the initial formulation, or ≥600 mg of the micronized formulation
- ORR in iNHL for patients treated at Higher Doses was not only greater with the combo (55%) as opposed to monotherapy (41%), but the depth of response was significantly greater with the addition of UTX (CR rate of 5% for monotherapy vs. 30% for the combo)
- Similarly, 3 complete responses observed in patients with DLBCL treated at Higher Doses occurred in patients receiving TGR + UTX
- A strong dose response was observed, with patients exposed to 800 mg of the micronized formulation achieving higher rates of response


## Study Design

### TGR-1202-101: TGR-1202 Monotherapy


Study TGR-1202-101 (NCT01767766) is a first-in-human, Phase I study of TGR-1202 in patients with relapsed or refractory hematologic malignancies

- TGR-1202 dosed orally once-daily (QD) in continuous 28 Day Cycles
- Dose-limiting toxicities (DLTs) assessed in Cycle 1 prior to escalation
- Intra-patient dose escalation allowed for patients in previous cohorts following establishment of safety at higher doses

#### 3+3 Dose Escalation Schema:



#### Micronized TGR-1202 Dose Escalation Schema:



### UTX-TGR-103: TGR-1202 in Combination with Ublituximab

Study UTX-TGR-103 (NCT02006485) is a Ph I/Ib trial evaluating the combination of ublituximab + TGR-1202 in patients with relapsed or refractory NHL and CLL. The study is divided into two parts:


- Phase I:** 3+3 escalation evaluating Cycle 1 DLTs
- Phase Ib:** Dose Expansion

#### Dose Escalation Schema:

Cohort	UTX Dose	TGR Dose (QD)
1	900/600 mg NHL/CLL	800 mg
2	900/600 mg NHL/CLL	1200 mg
3	900 mg	400 mg (micronized)
4	900 mg	600 mg (micronized)
5	900 mg	800 mg (micronized)
6	900 mg	1000 mg (micronized)
7	900 mg	1200 mg (micronized)
Expansion	TGR-1202 at 800 mg, 1000 mg, and 1200 mg micronized	

### Treatment Schedule:


Efficacy is assessed Week 8, and every 12 weeks thereafter. After Month 12, all patients remain on TGR-1202 single agent. Ublituximab was initially administered on Days 1, 8 and 15 of Cycles 1 & 2 and Day 1 of Cycles 4, 6, 9 & 12. The protocol was amended to use a more convenient schedule as follows:



## UNITY Registration Program

### Phase 2b UNITY-DLBCL Study

- Enrolling patients with previously treated DLBCL of all subtypes
- US Study Chair: Owen A. O'Connor, MD, PhD
- Ex-US Study Chair: Pier-Luigi Zinzani, MD, PhD



## Conclusions

- TGR-1202 is well tolerated and highly active in a broad population of heavily pretreated & high-risk patients with NHL as well as CLL (see EHA 2016 Poster P207), with the addition of ublituximab to TGR-1202 exhibiting greater frequency and depth of response over TGR-1202 monotherapy
- Discontinuations due to adverse events have been limited (~8%); GR3/4 events most associated with PI3K delta inhibitors have been rare, including pneumonia (~5%) and pneumonitis (<1.5%), ALT/AST elevations (~3%) and colitis (<1.5%), the latter occurring with no apparent association to time on therapy
- Safety profile supports additional multi-drug regimens: triple therapy combinations adding novel agents to ublituximab and TGR-1202 are ongoing (including ibrutinib, bendamustine, and pembrolizumab) with additional triple therapy studies planned
- Marked activity observed in DLBCL being explored further in registration directed UNITY-DLBCL Phase 2b Study, with a UNITY-iNHL study to commence by YE 2016. A Phase 3 study in patients with CLL, the UNITY-CLL study, is currently underway